Second-line treatment in the context of the IFM 95-01 trial
. | MP, no. . | M-DEX, no. . | DEX, no. . | DEX-IFN, no. . |
|---|---|---|---|---|
| No. patients | 122 | 118 | 127 | 121 |
| DEX | 20 | 4 | 1 | 1 |
| VAD | 35 | 26 | 8 | 4 |
| Alkylating agent–based regimens | 32 | 45 | 86 | 84 |
| Other | 5 | 6 | 4 | 4 |
| None | 28 | 33 | 24 | 24 |
| Unknown | 2 | 4 | 4 | 4 |
. | MP, no. . | M-DEX, no. . | DEX, no. . | DEX-IFN, no. . |
|---|---|---|---|---|
| No. patients | 122 | 118 | 127 | 121 |
| DEX | 20 | 4 | 1 | 1 |
| VAD | 35 | 26 | 8 | 4 |
| Alkylating agent–based regimens | 32 | 45 | 86 | 84 |
| Other | 5 | 6 | 4 | 4 |
| None | 28 | 33 | 24 | 24 |
| Unknown | 2 | 4 | 4 | 4 |